Alcohol Addiction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2000
Buy Report

Published: March 31, 2022 Report Code: GMDGDHC22015IDB-ST

Select Item

The Alcohol Addiction pipeline market research report provides comprehensive information on the therapeutics under development for Alcohol Addiction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Alcohol Addiction and features dormant and discontinued projects.

What are the key targets in the Alcohol Addiction pipeline market?

The key targets in the Alcohol Addiction pipeline market are Mu Type Opioid Receptor, 5-Hydroxytryptamine Receptor 2A, Glutamate Ionotropic Receptor NMDA Type Subunit, Delta Type Opioid Receptor 1, Gamma-Aminobutyric Acid Type B Receptor Subunit (Gamma Aminobutyric Acid), Glucocorticoid Receptor, Kappa Type Opioid Receptor, Sodium Dependent Dopamine Transporter, Sodium Dependent Noradrenaline Transporter, and 5-Hydroxytryptamine Receptor 3.

Alcohol Addiction pipeline market, by targets

Alcohol Addiction pipeline market, by targets

For more target insights, download a free report sample

What are the key MoA in the Alcohol Addiction pipeline market?

The key MoA in the Alcohol Addiction pipeline market are Mu Type Opioid Receptor Antagonist, 5-Hydroxytryptamine Receptor 2A Agonist, Glutamate Ionotropic Receptor NMDA Type Subunit Antagonist, Delta Type Opioid Receptor Antagonist, Gamma-Aminobutyric Acid Type B Receptor Subunit (Gamma Aminobutyric Acid Agonist), Glucocorticoid Receptor Antagonist, Kappa Type Opioid Receptor Antagonist, Sodium Dependent Dopamine Transporter Inhibitor, Sodium Dependent Noradrenaline Transporter Inhibitor, and 5-Hydroxytryptamine Receptor 2A Antagonist.

Alcohol Addiction pipeline market, by MoA

Alcohol Addiction pipeline market, by MoA

For more MoA insights, download a free report sample

What are the key RoA in the Alcohol Addiction pipeline market?

The key RoA in the Alcohol Addiction pipeline market are Oral, Subcutaneous, Intravenous, Intramuscular, Transdermal, Inhalational, Nasal, and Sublingual. Oral has the highest number of pipeline market in the Alcohol Addiction pipeline market.

Alcohol Addiction pipeline market, by RoA

Alcohol Addiction pipeline market, by RoA

For more RoA insights, download a free report sample

What are the key small molecule in the Alcohol Addiction pipeline market?

The key small molecule in the Alcohol Addiction pipeline market are Small Molecule, Antisense RNAi Oligonucleotide, Enzyme, and Peptide. Small Molecule has the highest number of pipeline products in the Alcohol Addiction pipeline market.

Alcohol Addiction pipeline market, by small molecule

Alcohol Addiction pipeline market, by small molecule

For more small molecule insights, download a free report sample

What are the key companies in the Alcohol Addiction pipeline market?

The key companies in the Alcohol Addiction pipeline market are BioCorRx Inc, Adial Pharmaceuticals Inc, Astraea Therapeutics LLC, AWAKN Life Sciences Corp, Clairvoyant Therapeutics Inc, Corcept Therapeutics Inc, Lohocla Research Corp, Addex Therapeutics Ltd, Alar Pharmaceuticals Inc, and Aptinyx Inc.

Alcohol Addiction pipeline market, by companies

Alcohol Addiction pipeline market, by companies

To know more about key companies, download a free report sample

Market report overview

Key targets Mu Type Opioid Receptor, 5-Hydroxytryptamine Receptor 2A, Glutamate Ionotropic Receptor NMDA Type Subunit, Delta Type Opioid Receptor 1, Gamma-Aminobutyric Acid Type B Receptor Subunit (Gamma Aminobutyric Acid), Glucocorticoid Receptor, Kappa Type Opioid Receptor, Sodium Dependent Dopamine Transporter, Sodium Dependent Noradrenaline Transporter, and 5-Hydroxytryptamine Receptor 3
Key MoA Mu Type Opioid Receptor Antagonist, 5-Hydroxytryptamine Receptor 2A Agonist, Glutamate Ionotropic Receptor NMDA Type Subunit Antagonist, Delta Type Opioid Receptor Antagonist, Gamma-Aminobutyric Acid Type B Receptor Subunit (Gamma Aminobutyric Acid Agonist), Glucocorticoid Receptor Antagonist, Kappa Type Opioid Receptor Antagonist, Sodium Dependent Dopamine Transporter Inhibitor, Sodium Dependent Noradrenaline Transporter Inhibitor, and 5-Hydroxytryptamine Receptor 2A Antagonist
Key RoA Oral, Subcutaneous, Intravenous, Intramuscular, Transdermal, Inhalational, Nasal, and Sublingual
Key molecule type Small Molecule, Antisense RNAi Oligonucleotide, Enzyme, and Peptide
Key companies BioCorRx Inc, Adial Pharmaceuticals Inc, Astraea Therapeutics LLC, AWAKN Life Sciences Corp, Clairvoyant Therapeutics Inc, Corcept Therapeutics Inc, Lohocla Research Corp, Addex Therapeutics Ltd, Alar Pharmaceuticals Inc, and Aptinyx Inc

 

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Alcohol Addiction (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Alcohol Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Alcohol Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Alcohol Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Alcohol Addiction (Central Nervous System)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Alcohol Addiction (Central Nervous System).

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding Alcohol Addiction (Central Nervous System) pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Addex Therapeutics Ltd
Adial Pharmaceuticals Inc
Alar Pharmaceuticals Inc
Aptinyx Inc
Astellas Pharma Inc
Astraea Therapeutics LLC
Avicanna Inc
AWAKN Life Sciences Corp
BioCorRx Inc
Bioprojet SCR
Ceruvia Lifesciences LLC
Chronos Therapeutics Ltd
Clairvoyant Therapeutics Inc
Clearmind Medicine Inc
Colorado Research Partners LLC
Confluence Pharmaceuticals LLC
Corcept Therapeutics Inc
Curemark LLC
Cybin Inc
Eli Lilly and Co
Journey Colab Corp
Kinnov Therapeutics
Kinoxis Therapeutics Pty Ltd
Kyorin Pharmaceutical Co Ltd
Laboratorio Farmaceutico CT Srl
Lohocla Research Corp
Mapreg SAS
Mind Medicine MindMed Inc
Montisera Ltd
Naprogenix Inc
Neuroepigenix LLC
Novo Nordisk AS
Omeros Corp
Opiant Pharmaceuticals Inc
Orphomed Inc
Osmotica Pharmaceutical Corp
Palisades Therapeutics
Pfizer Inc
Protagenic Therapeutics Inc
Psilera Inc
Sage Therapeutics Inc
SK Biopharmaceuticals Co Ltd
Sobrera Pharma AB
South Plains Biotechnology Inc
Syntropharma Ltd
Tonix Pharmaceuticals Holding Corp
VM Discovery Inc
Whan In Pharm Co Ltd
Zynerba Pharmaceuticals Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Alcohol Addiction – Overview

Alcohol Addiction – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Alcohol Addiction – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Alcohol Addiction – Companies Involved in Therapeutics Development

Addex Therapeutics Ltd

Adial Pharmaceuticals Inc

Alar Pharmaceuticals Inc

Aptinyx Inc

Astellas Pharma Inc

Astraea Therapeutics LLC

Avicanna Inc

AWAKN Life Sciences Corp

BioCorRx Inc

Bioprojet SCR

Ceruvia Lifesciences LLC

Chronos Therapeutics Ltd

Clairvoyant Therapeutics Inc

Clearmind Medicine Inc

Colorado Research Partners LLC

Confluence Pharmaceuticals LLC

Corcept Therapeutics Inc

Curemark LLC

Cybin Inc

Eli Lilly and Co

Journey Colab Corp

Kinnov Therapeutics

Kinoxis Therapeutics Pty Ltd

Kyorin Pharmaceutical Co Ltd

Laboratorio Farmaceutico CT Srl

Lohocla Research Corp

Mapreg SAS

Mind Medicine MindMed Inc

Montisera Ltd

Naprogenix Inc

Neuroepigenix LLC

Novo Nordisk AS

Omeros Corp

Opiant Pharmaceuticals Inc

Orphomed Inc

Osmotica Pharmaceutical Corp

Palisades Therapeutics

Pfizer Inc

Protagenic Therapeutics Inc

Psilera Inc

Sage Therapeutics Inc

SK Biopharmaceuticals Co Ltd

Sobrera Pharma AB

South Plains Biotechnology Inc

Syntropharma Ltd

Tonix Pharmaceuticals Holding Corp

VM Discovery Inc

Whan In Pharm Co Ltd

Zynerba Pharmaceuticals Inc

Alcohol Addiction – Drug Profiles

(cyproheptadine hydrochloride + prazosin hydrochloride) – Drug Profile

Product Description

Mechanism Of Action

History of Events

(varenicline tartrate + bupropion hydrochloride) SR – Drug Profile

Product Description

Mechanism Of Action

acamprosate calcium SR – Drug Profile

Product Description

Mechanism Of Action

History of Events

ADX-71441 – Drug Profile

Product Description

Mechanism Of Action

History of Events

ALA-2000 – Drug Profile

Product Description

Mechanism Of Action

arbaclofen ER – Drug Profile

Product Description

Mechanism Of Action

ASP-8062 – Drug Profile

Product Description

Mechanism Of Action

History of Events

AT-1001 – Drug Profile

Product Description

Mechanism Of Action

BICX-101 SR – Drug Profile

Product Description

Mechanism Of Action

History of Events

BICX-102 – Drug Profile

Product Description

Mechanism Of Action

History of Events

BP-1.3656B – Drug Profile

Product Description

Mechanism Of Action

History of Events

brexanolone – Drug Profile

Product Description

Mechanism Of Action

History of Events

CM-1212 – Drug Profile

Product Description

Mechanism Of Action

CMND-100 – Drug Profile

Product Description

Mechanism Of Action

History of Events

CTDP-002 – Drug Profile

Product Description

Mechanism Of Action

History of Events

CYB-003 – Drug Profile

Product Description

Mechanism Of Action

History of Events

D-15 – Drug Profile

Product Description

Mechanism Of Action

DCRALDH-2 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Drugs to Inhibit Fructokinase for Alcohol Addiction – Drug Profile

Product Description

Mechanism Of Action

History of Events

GET-73 – Drug Profile

Product Description

Mechanism Of Action

History of Events

ibudilast – Drug Profile

Product Description

Mechanism Of Action

History of Events

JOUR-001 – Drug Profile

Product Description

Mechanism Of Action

JR-220 – Drug Profile

Product Description

Mechanism Of Action

History of Events

ketamine – Drug Profile

Product Description

Mechanism Of Action

History of Events

KNX-100 – Drug Profile

Product Description

Mechanism Of Action

MAP-4343 – Drug Profile

Product Description

Mechanism Of Action

midomafetamine – Drug Profile

Product Description

Mechanism Of Action

History of Events

mifepristone – Drug Profile

Product Description

Mechanism Of Action

History of Events

MQ-221 – Drug Profile

Product Description

Mechanism Of Action

naltrexone – Drug Profile

Product Description

Mechanism Of Action

naltrexone hydrochloride – Drug Profile

Product Description

Mechanism Of Action

History of Events

naltrexone hydrochloride – Drug Profile

Product Description

Mechanism Of Action

History of Events

naltrexone LA – Drug Profile

Product Description

Mechanism Of Action

History of Events

Nezavist – Drug Profile

Product Description

Mechanism Of Action

History of Events

NYPRG-101 – Drug Profile

Product Description

Mechanism Of Action

NYX-783 – Drug Profile

Product Description

Mechanism Of Action

History of Events

odelepran – Drug Profile

Product Description

Mechanism Of Action

History of Events

OMS-527 – Drug Profile

Product Description

Mechanism Of Action

History of Events

ondansetron hydrochloride – Drug Profile

Product Description

Mechanism Of Action

History of Events

ORP-106 – Drug Profile

Product Description

Mechanism Of Action

PF-05190457 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Pharmacotherapy for Alcohol Use Disorder – Drug Profile

Product Description

Mechanism Of Action

History of Events

PSIL-002 – Drug Profile

Product Description

Mechanism Of Action

psilocybin – Drug Profile

Product Description

Mechanism Of Action

psilocybin – Drug Profile

Product Description

Mechanism Of Action

PT-00114 – Drug Profile

Product Description

Mechanism Of Action

History of Events

PT-150 – Drug Profile

Product Description

Mechanism Of Action

History of Events

RC-132 – Drug Profile

Product Description

Mechanism Of Action

RTI-1395133 – Drug Profile

Product Description

Mechanism Of Action

SKL-10406 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Antagonize Mu Opioid Receptor for Drug Abuse, Alcohol Addiction and OIC – Drug Profile

Product Description

Mechanism Of Action

Small Molecule to Antagonize NMDA Receptor and Block Sodium Channels for CNS disorders – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules for Alcohol Use Disorder – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules for Psychiatric Disorders – Drug Profile

Product Description

Mechanism Of Action

Small Molecules To Agonize Nociceptin Receptors For Alcohol Addiction – Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Antagonize GABAA1 for Alcohol Addiction and Anxiety – Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Antagonize Glucocorticoid Receptor II for Alcohol Dependance – Drug Profile

Product Description

Mechanism Of Action

TNX-102 – Drug Profile

Product Description

Mechanism Of Action

VMD-2202 – Drug Profile

Product Description

Mechanism Of Action

History of Events

WIL-1903 – Drug Profile

Product Description

Mechanism Of Action

zolunicant hydrochloride – Drug Profile

Product Description

Mechanism Of Action

History of Events

Alcohol Addiction – Dormant Projects

Alcohol Addiction – Discontinued Products

Alcohol Addiction – Product Development Milestones

Featured News & Press Releases

Mar 17, 2022: Clearmind Medicine announces positive results on CMND-100 trials

Feb 28, 2022: MediciNova announces MN-166 (ibudilast) identified as potential beneficial pharmacotherapy for treatment of degenerative cervical myelopathy in Global Spine Journal

Feb 24, 2022: Adial Pharmaceuticals announces completion of last patient, last visit in its ONWARD phase 3 trial of AD04 for the treatment of patients with alcohol use disorder

Feb 22, 2022: MediciNova announces MN-166 (ibudilast) identified as promising pharmacotherapy for alcohol use disorder in drugs

Jan 28, 2022: Clearmind Medicine partners with Dr. Gabor Mate to discuss alcohol use disorder and trauma in a special virtual Event on February 3

Jan 27, 2022: MediciNova receives a notice of intention to grant for a new patent covering MN-166 (ibudilast) for the treatment of alcohol use disorder in Europe

Jan 20, 2022: Opiant Pharmaceuticals announces first patient dosed in phase 2 trial of OPNT002, nasal Naltrexone, for alcohol use disorder

Jan 20, 2022: Clairvoyant Therapeutics receives approval in Canada to initiate a world-leading psilocybin trial for treatment of alcohol use disorder

Jan 19, 2022: Awakn Life Sciences signs MOU With MAPS

Jan 11, 2022: Awakn announces positive results from phase II A/B clinical trial

Dec 08, 2021: Cybin confirms scientific advice meeting with UK Medical and Healthcare Products Regulatory Agency for lead candidate CYB003 for the treatment of major depressive disorder and alcohol use disorder

Nov 16, 2021: Awakn Life Sciences signs MOU with NHS (Devon Partnership NHS Trust) and University of Exeter with a view of increasing access to psychedelic-assisted psychotherapy in the UK

Nov 08, 2021: Cybin announces positive CYB003 data demonstrating significant advantages over oral psilocybin for treatment of mental health

Nov 04, 2021: Awakn Life Sciences announces the findings from phase II A/B study are to be published In American Journal Of Psychiatry

Oct 26, 2021: Clearmind signs development and supply agreement to produce its drug candidate MEAI psychedelic molecule with Aragen Life Sciences

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Alcohol Addiction, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Companies, 2022 (Contd..1)

Number of Products under Development by Companies, 2022 (Contd..2)

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022 (Contd..2)

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Target, 2022 (Contd..1)

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Alcohol Addiction – Pipeline by Addex Therapeutics Ltd, 2022

Alcohol Addiction – Pipeline by Adial Pharmaceuticals Inc, 2022

Alcohol Addiction – Pipeline by Alar Pharmaceuticals Inc, 2022

Alcohol Addiction – Pipeline by Aptinyx Inc, 2022

Alcohol Addiction – Pipeline by Astellas Pharma Inc, 2022

Alcohol Addiction – Pipeline by Astraea Therapeutics LLC, 2022

Alcohol Addiction – Pipeline by Avicanna Inc, 2022

Alcohol Addiction – Pipeline by AWAKN Life Sciences Corp, 2022

Alcohol Addiction – Pipeline by BioCorRx Inc, 2022

Alcohol Addiction – Pipeline by Bioprojet SCR, 2022

Alcohol Addiction – Pipeline by Ceruvia Lifesciences LLC, 2022

Alcohol Addiction – Pipeline by Chronos Therapeutics Ltd, 2022

Alcohol Addiction – Pipeline by Clairvoyant Therapeutics Inc, 2022

Alcohol Addiction – Pipeline by Clearmind Medicine Inc, 2022

Alcohol Addiction – Pipeline by Colorado Research Partners LLC, 2022

Alcohol Addiction – Pipeline by Confluence Pharmaceuticals LLC, 2022

Alcohol Addiction – Pipeline by Corcept Therapeutics Inc, 2022

Alcohol Addiction – Pipeline by Curemark LLC, 2022

Alcohol Addiction – Pipeline by Cybin Inc, 2022

Alcohol Addiction – Pipeline by Eli Lilly and Co, 2022

Alcohol Addiction – Pipeline by Journey Colab Corp, 2022

Alcohol Addiction – Pipeline by Kinnov Therapeutics, 2022

Alcohol Addiction – Pipeline by Kinoxis Therapeutics Pty Ltd, 2022

Alcohol Addiction – Pipeline by Kyorin Pharmaceutical Co Ltd, 2022

Alcohol Addiction – Pipeline by Laboratorio Farmaceutico CT Srl, 2022

Alcohol Addiction – Pipeline by Lohocla Research Corp, 2022

Alcohol Addiction – Pipeline by Mapreg SAS, 2022

Alcohol Addiction – Pipeline by Mind Medicine MindMed Inc, 2022

Alcohol Addiction – Pipeline by Montisera Ltd, 2022

Alcohol Addiction – Pipeline by Naprogenix Inc, 2022

Alcohol Addiction – Pipeline by Neuroepigenix LLC, 2022

Alcohol Addiction – Pipeline by Novo Nordisk AS, 2022

Alcohol Addiction – Pipeline by Omeros Corp, 2022

Alcohol Addiction – Pipeline by Opiant Pharmaceuticals Inc, 2022

Alcohol Addiction – Pipeline by Orphomed Inc, 2022

Alcohol Addiction – Pipeline by Osmotica Pharmaceutical Corp, 2022

Alcohol Addiction – Pipeline by Palisades Therapeutics, 2022

Alcohol Addiction – Pipeline by Pfizer Inc, 2022

Alcohol Addiction – Pipeline by Protagenic Therapeutics Inc, 2022

Alcohol Addiction – Pipeline by Psilera Inc, 2022

Alcohol Addiction – Pipeline by Sage Therapeutics Inc, 2022

Alcohol Addiction – Pipeline by SK Biopharmaceuticals Co Ltd, 2022

Alcohol Addiction – Pipeline by Sobrera Pharma AB, 2022

Alcohol Addiction – Pipeline by South Plains Biotechnology Inc, 2022

Alcohol Addiction – Pipeline by Syntropharma Ltd, 2022

Alcohol Addiction – Pipeline by Tonix Pharmaceuticals Holding Corp, 2022

Alcohol Addiction – Pipeline by VM Discovery Inc, 2022

Alcohol Addiction – Pipeline by Whan In Pharm Co Ltd, 2022

Alcohol Addiction – Pipeline by Zynerba Pharmaceuticals Inc, 2022

Alcohol Addiction – Dormant Projects, 2022

Alcohol Addiction – Dormant Projects, 2022 (Contd..1)

Alcohol Addiction – Dormant Projects, 2022 (Contd..2)

Alcohol Addiction – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Alcohol Addiction, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently asked questions

  • What are the key targets in the Alcohol Addiction pipeline market?

    The key targets in the Alcohol Addiction pipeline market are Mu Type Opioid Receptor, 5-Hydroxytryptamine Receptor 2A, Glutamate Ionotropic Receptor NMDA Type Subunit, Delta Type Opioid Receptor 1, Gamma-Aminobutyric Acid Type B Receptor Subunit (Gamma Aminobutyric Acid), Glucocorticoid Receptor, Kappa Type Opioid Receptor, Sodium Dependent Dopamine Transporter, Sodium Dependent Noradrenaline Transporter, and 5-Hydroxytryptamine Receptor 3.

  • What are the key MoA in the Alcohol Addiction pipeline market?

    The key MoA in the Alcohol Addiction pipeline market are Mu Type Opioid Receptor Antagonist, 5-Hydroxytryptamine Receptor 2A Agonist, Glutamate Ionotropic Receptor NMDA Type Subunit Antagonist, Delta Type Opioid Receptor Antagonist, Gamma-Aminobutyric Acid Type B Receptor Subunit (Gamma Aminobutyric Acid Agonist), Glucocorticoid Receptor Antagonist, Kappa Type Opioid Receptor Antagonist, Sodium Dependent Dopamine Transporter Inhibitor, Sodium Dependent Noradrenaline Transporter Inhibitor, and 5-Hydroxytryptamine Receptor 2A Antagonist.

  • What are the key RoA in the Alcohol Addiction pipeline market?

    The key RoA in the Alcohol Addiction pipeline market are Oral, Subcutaneous, Intravenous, Intramuscular, Transdermal, Inhalational, Nasal, and Sublingual.

  • What are the key small molecule in the Alcohol Addiction pipeline market?

    The key small molecule in the Alcohol Addiction pipeline market are Small Molecule, Antisense RNAi Oligonucleotide, Enzyme, and Peptide.

  • What are the key companies in the Alcohol Addiction pipeline market?

    The key companies in the Alcohol Addiction pipeline market are BioCorRx Inc, Adial Pharmaceuticals Inc, Astraea Therapeutics LLC, AWAKN Life Sciences Corp, Clairvoyant Therapeutics Inc, Corcept Therapeutics Inc, Lohocla Research Corp, Addex Therapeutics Ltd, Alar Pharmaceuticals Inc, and Aptinyx Inc.

Alcohol Addiction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update standard reports
Currency USD
$2,000

Can be used by individual purchaser only

Most Popular
$4,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Central Nervous System reports
Pharmaceuticals
New
New Drug Approvals and Their Contract Manufacture - 2024 Edition
$4,995 | April 2024
Pharmaceuticals
New
Antibody-Drug Conjugates (ADC) Overview, Industry Trends, Marketed and Pipeline Products,…
$6,995 | March 2024
Pharmaceuticals
New
Cell and Gene Therapies in Ophthalmology - Disease Overview, Treatment…
$6,995 | March 2024
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Alcohol Addiction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Alcohol Addiction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more